达罗瓦塞尔蒂布 (Darovasertib) 是一种用于转移性脑膜黑色素瘤的新疗法
Lei Cao1, Shuzhen Chen2, Rainie Sun3,4
1Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States.
Frontiers in pharmacology
|August 14, 2023
概括
一种新型蛋白质激酶C (PKC) 抑制剂Darovasertib在治疗阴道黑色素瘤方面表现有前途. 获得了孤儿药物指标,早期试验表明这种罕见的癌症与MEK抑制剂具有协同效应.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 卵巢黑色素瘤是一种罕见的眼睛癌症,具有高转移风险和不良预后.
- 激活蛋白激酶C (PKC) 和基因激活蛋白激酶通路,以及GNAQ/GNA11基因突变,是脑膜黑色素瘤发病的关键.
- 目前用于皮膜黑色素瘤的治疗方法存在局限性,需要新的治疗方法.
研究的目的:
- 审查用于皮膜黑色素瘤治疗药物的开发.
- 讨论darovasertib的作用机制,药理动力学,安全性和临床试验.
- 探索膜黑色素瘤治疗的未来研究方向.
主要方法:
- 审查关于皮膜黑色素瘤治疗和darovasertib的现有文献.
- 对darovasertib的临床前和临床数据的分析.
- 与其他PKC抑制剂相比,达罗瓦塞尔蒂布的比较.
主要成果:
- 达罗瓦塞尔蒂布是一种强效且耐受良好的口服PKC抑制剂.
- 当与MEK抑制剂 (binimetinib或crizotinib) 结合使用时,Darovasertib在皮膜黑色素瘤中表现出协同效应.
- 达罗瓦塞尔蒂布被授予孤儿药物指标,用于皮膜黑色素瘤治疗.
结论:
- 达罗瓦塞尔蒂布代表了一种有前途的针对性治疗线膜黑色素瘤.
- 与MEK抑制剂的联合治疗可能会提高darovasertib的疗效.
- 进一步的研究是有必要的,以优化darovasertib治疗策略的毛膜黑色素瘤.
关键词:
在GNAQ/11上在PKC抑制剂中使用PKC抑制剂.比尼米丁尼比尼米丁尼比尼米丁尼克里佐丁尼布 (crizotinib) 的使用方法达罗瓦斯维尔蒂布 (达罗瓦斯维尔蒂布) 在转移性阴膜性黑色素瘤更多相关视频
05:46Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
1.7K
06:46Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Published on: September 4, 2021
1.4K
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K